Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab for quality of life and angioedema in chronic spontaneous urticaria
2011-004254-25Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic idiopathic urticaria (CIU) comparing omalizumab with placebo (2 arms). Primary endpoint: Change from baseline to week 28 in CU-Q2oL total score. Started Mar 2012; status: completed.
02
Drugs
omalizumab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on 2011-004254-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004254-25.